CAR-Natural Killer Cells Show the Promising insights in Personalized Medicine of Cancer
- سال انتشار: 1397
- محل انتشار: سومین کنگره بین المللی پزشکی شخصی ایران
- کد COI اختصاصی: IPMCMED03_058
- زبان مقاله: انگلیسی
- تعداد مشاهده: 739
نویسندگان
Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
چکیده
IntroductionNatural Killer Cells (NK cells) have a critical role in innate immune system. The new generation of genetically modified NK cells are CAR-NKs. They can function as a tumor-specific standardized characterized products. Due to their ability in specific tumor recognition, he have decided to do a comprehensive study in this area.MethodsRelevant English-language literature were searched and retrieved from PubMed search engine and https://clinicaltrials.gov (2008-2018). The following keywords were used: CAR-NK , CAR-Natural Killer Cells , Cancer and Personalized medicine .ResultsUntil now, 4 clinical trials have been started in using CAR-NK cells for cancer treatment. Two of them focused on neuroblastoma in Texas Children s Hospital. One of them was withdrawn. 24 patients were recruited for the second one. This group wanted to use GD2-specific CARS and for further antitumor activity added another gene expressing IL-15. They have not reported any result so far. The third one was started by MD Anderson cancer center. They have recruited 36 patients (7-80 years old) with relapsed/refractory CD19+ B lymphoid malignancies. They wanted to use CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients. No reported no results until now. And the last study was again begun by MD Anderson cancer center. They aimed to assess the immunotherapy with ex vivo-expanded cord blood-derived CAR-NK cells combined with high-dose chemotherapy and autologous stem cell transplantation for patients (18-70 years old) with B-cell lymphoma and they announced no results so far.ConclusionBased on the results of in-vitro and pre-clinical studies, the specifity of CAR-NK cells to cancer cells has made them a valuable candidate for clinical trials. However, the use of CAR-NK cells needs more examination to be proofed as a suitable therapeutic approach.Conflict of InterestThe authors declare no conflict of interest.کلیدواژه ها
CAR-Natural Killer Cells, Personalized Medicine, Cancer Therapyمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.